Predictive Oncology (NASDAQ:POAI) Share Price Crosses Below 200-Day Moving Average of $3.00

Predictive Oncology Inc. (NASDAQ:POAI) shares crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.00 and traded as low as $1.35. Predictive Oncology shares last traded at $1.39, with a volume of 28,250 shares traded.

Predictive Oncology Trading Down 11.4 %

The stock has a market capitalization of $4.67 million, a PE ratio of -0.33 and a beta of 1.28. The company’s 50 day simple moving average is $2.62 and its 200 day simple moving average is $2.98.

Predictive Oncology (NASDAQ:POAI) last released its earnings results on Thursday, March 28th. The medical instruments supplier reported ($0.85) EPS for the quarter. The firm had revenue of $0.34 million during the quarter. Predictive Oncology had a negative return on equity of 104.21% and a negative net margin of 785.62%.

Institutional Trading of Predictive Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in shares of Predictive Oncology in the 4th quarter valued at $25,000. Carnegie Mellon University acquired a new position in shares of Predictive Oncology in the 4th quarter valued at $34,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Predictive Oncology in the 1st quarter valued at $54,000. Citadel Advisors LLC acquired a new position in shares of Predictive Oncology in the 3rd quarter valued at $65,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Predictive Oncology by 26.9% in the 4th quarter. Renaissance Technologies LLC now owns 302,724 shares of the medical instruments supplier’s stock valued at $93,000 after purchasing an additional 64,261 shares during the last quarter. 9.04% of the stock is owned by hedge funds and other institutional investors.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.